Cannabis pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "cannabis pharmacology"
Cannabis Pharmacology: Cannabinoids, Receptors, and the Endocannabinoid System
Cannabis sativa contains over 140 phytocannabinoids, with Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most studied. These cannabinoids interact primarily with the endocannabinoid system (ECS), which includes cannabinoid receptors CB1 and CB2. THC acts as a partial agonist at CB1 receptors, producing psychoactive effects and modulating pain, appetite, and anxiety, while CB2 activation is linked to anti-inflammatory effects. CBD, the major non-psychoactive component, acts as a partial agonist or antagonist at these receptors and can modulate the effects of THC, often reducing its psychoactive side effects 1256+4 MORE.
Minor Cannabinoids and Multitarget Pharmacology
Beyond THC and CBD, cannabis contains many minor cannabinoids such as cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV). These compounds also interact with CB1 and CB2 receptors, as well as other targets like transient receptor potential (TRP) channels, peroxisome proliferator-activated receptors (PPARs), and serotonin receptors (5-HT1a). This multitarget activity underlies the broad therapeutic potential of cannabis, including possible benefits for neuropathic pain, epilepsy, neurodegenerative diseases, and inflammation 1789.
Pharmacological Effects and Therapeutic Uses
Cannabis and its cannabinoids have demonstrated analgesic, anti-emetic, anti-inflammatory, anti-seizure, and neuroprotective properties. THC is primarily responsible for psychoactive effects, while both THC and CBD contribute to pain relief and muscle spasticity reduction. Medical cannabis is used for conditions such as chronic pain, epilepsy, cancer palliation, multiple sclerosis, and Parkinson’s disease. However, the efficacy of these treatments is still being evaluated, and more well-controlled clinical trials are needed 3568+2 MORE.
Administration, Dosing, and Safety Considerations
Cannabis can be administered by smoking, vaporization, or orally. The method of administration affects the onset and duration of effects. THC doses should generally be limited to 30 mg/day or less to minimize psychoactive side effects, and combining THC with CBD can help reduce anxiety and tachycardia. CBD often requires higher doses for therapeutic effects. Dose titration should be gradual, and patient monitoring is important to manage potential drug interactions and adverse events 3410.
Risks, Side Effects, and Public Health Concerns
Cannabis use is associated with dose-related impairments in psychomotor and cognitive performance, which can affect activities such as driving. Other risks include respiratory and cardiovascular effects similar to tobacco smoke, increased risk of schizophrenia with adolescent use, memory and cognition impairments, and accidental pediatric ingestions. The lack of specificity in cannabinoid-derived drugs and the potential for unpleasant side effects limit their therapeutic use. Legalization and improved research access are expected to address many of these concerns and clarify the safety profile of medical cannabis 2456+1 MORE.
Conclusion
Cannabis pharmacology is complex, involving a wide range of cannabinoids that interact with multiple molecular targets. While THC and CBD are the most studied, minor cannabinoids also show significant pharmacological activity and therapeutic promise. The therapeutic potential of cannabis is broad, but careful dosing, monitoring, and further research are needed to maximize benefits and minimize risks.
Sources and full results
Most relevant research papers on this topic